Evidence map›Paper›PMID 38765733›Full record

ArticleCase reports in oncological medicine2024

Li-Fraumeni Syndrome With Six Primary Tumors-Case Report.

Dejan Stojiljković, Ana Cvetković, Andrej Jokić, Dijana Mirčić, Sanja Mihajlović, Ana Krivokuća, Marija Đorđić Crnogorac, Lazar Glisic

Abstract readCase Reports
In one paragraph

Article in Case reports in oncological medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dejan StojiljkovićDepartment of Surgery, Surgical Oncology Clinic, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Ana CvetkovićFaculty of Medicine, University of Belgrade, Belgrade, Serbia.
Andrej JokićDepartment of Anesthesiology With Reanimatology and Intensive Care Unit, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Dijana MirčićDepartment of Anesthesiology With Reanimatology and Intensive Care Unit, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Sanja MihajlovićDepartment of Surgery, Surgical Oncology Clinic, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Ana KrivokućaDepartment for Experimental Research and Genetics, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Marija Đorđić CrnogoracDepartment for Experimental Research and Genetics, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.
Lazar GlisicDepartment of Obstetrics and Gynecology, University Clinic Ulm, Faculty of Medicine, University of Ulm, Ulm, Germany.ORCID https://orcid.org/0009-0003-1446-210X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Li-Fraumeni syndrome (LFS) is a cancer predisposition syndrome associated with a high, lifetime risk of a broad spectrum of cancers caused by pathogenic germline TP53 mutations. Numerous different germline TP53 mutations have been associated with LFS, which has an exceptionally diverse clinical spectrum in terms of tumor type and age of onset. Our patient has developed six asynchronous tumors to date: a phyllode tumor of the breast, a pheochromocytoma, a rosette-forming glioneuronal tumor (RGNT), an adrenocortical carcinoma (ACC), a ductal carcinoma of the breast, and a thymoma. The occurrence of such a number of rare tumors is sporadic even among in the population of patients living with cancer predisposition syndromes. In this instance, the omission of pretest genetic counseling and thorough family tree analysis prior to selecting the test led to the oversight of an underlying TP53 likely pathogenic mutation (classified as Class 4). This emphasizes the necessity for such counseling to prevent overlooking crucial genetic information. Neglecting this step could have had profound implications on the patient's treatment, particularly considering the early onset and occurrence of multiple tumors, which typically raise suspicion of a hereditary component. The implications for family members must be considered.

Indexed as

case reportLi-Fraumenimitotanep53

Identifiers

PMID38765733
PMCPMC11101246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.